Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)

Jürgen Krauter, Walter Fiedler, Richard F. Schlenk, Peter Paschka, Felicitas Thol, Michael Lübbert, Mohammed Wattad, Mareike Verbeek, Christian Könecke, Barbara Neuhaus, Armin Papkalla, Maxim Kebenko, Melanie Janning, Konstanze Döhner, Verena I. Gaidzik, Heiko Becker, Christine Greil, Peter Reimer, Katharina S. Götze, Hartmut DöhnerArnold Ganser, Michael Heuser

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry